1
|
Fine RL, Mao Y, Garcia-Carracedo D, Su GH, Qiu W, Hochfeld U, Nichols G, Li YL, Dinnen RD, Raffo A, Brandt-Rauf PW. Gene Therapy with p14/ tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines 2023; 11:258. [PMID: 36830797 PMCID: PMC9953161 DOI: 10.3390/biomedicines11020258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 07/15/2022] [Accepted: 07/21/2022] [Indexed: 01/21/2023] Open
Abstract
Any gene therapy for cancer will be predicated upon its selectivity against cancer cells and non-toxicity to normal cells. Therefore, safeguards are needed to prevent its activation in normal cells. We designed a minimal p14ARF promoter with upstream Ap1 and E2F enhancer elements and a downstream MDR1 inhibitory element, TATA box, and a transcription initiation site (hereafter p14ARFmin). The modified p14ARFmin promoter was linked to bicistronic P14 and truncated BID (tBID) genes, which led to synergistic apoptosis via the intrinsic and extrinsic pathways of apoptosis when expressed. The promoter was designed to be preferentially activated by mutant Ras and completely inhibited by wild-type p53 so that only cells with both mutant Ras and mutant p53 would activate the construct. In comparison to most p53 gene therapies, this construct has selective advantages: (1) p53-based gene therapies with a constitutive CMV promoter cannot differentiate between normal cells and cancer cells, and can be toxic to normal cells; (2) our construct does not induce p21WAF/CIPI in contrast to other p53-based gene therapies, which can induce cell cycle arrest leading to increased chemotherapy resistance; (3) the modified construct (p14ARFmin-p14-tBID) demonstrates bidirectional control of its promoter, which is completely repressed by wild-type p53 and activated only in cells with both RAS and P53 mutations; and (4) a novel combination of genes (p14 and tBID) can synergistically induce potent intrinsic and extrinsic apoptosis in cancer cells.
Collapse
Affiliation(s)
- Robert L. Fine
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Yuehua Mao
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Dario Garcia-Carracedo
- Department Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH–Columbia University Medical Center, New York, NY 10032, USA
| | - Gloria H. Su
- Department Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH–Columbia University Medical Center, New York, NY 10032, USA
| | - Wanglong Qiu
- Department Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH–Columbia University Medical Center, New York, NY 10032, USA
| | - Uri Hochfeld
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Gwen Nichols
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Yong-Liang Li
- Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
- School of Public Health, University of Illinois at Chicago, Chicago, IL 60612, USA
| | - Richard D. Dinnen
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Anthony Raffo
- Experimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA
| | - Paul W. Brandt-Rauf
- Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
- School of Public Health, University of Illinois at Chicago, Chicago, IL 60612, USA
- School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, USA
| |
Collapse
|
2
|
Abstract
Apoptosis, a form of programmed cell death that is important for development and homeostasis, is regulated by the BCL-2 family of proteins. Over twenty BCL-2 family members have been classified in three groups based on structural homology and function. The multidomain antiapoptotic proteins promote survival, whereas the multidomain and the BH3-only proapoptotic members induce cell death. Because the interaction among the BCL-2 family members occurs primarily at the mitochondrial outer membrane, biochemical assays using artificial liposomes have been developed to study the functional relationship between these proteins. The liposomal permeabilization assay is a cell-free system that relies on the ability of multidomain pro-apoptotic members to promote membrane permeabilization upon activation. By encapsulating a fluorophore and a quencher into liposomes, the degree of permeabilization can be quantified by the increase in fluorescence intensity as the fluorophore and quencher dissociate. The liposomal permeabilization assay has been used to delineate interactions among BCL-2 family members as well as to characterize peptides, small molecules, and lipids that modulate the function of BCL-2 family of proteins. Here, we describe in detail the permeabilization of liposomes induced by the interaction between BAX and BH3-only activator tBID.
Collapse
Affiliation(s)
- Denis E Reyna
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA
- Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA
- Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Evripidis Gavathiotis
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
- Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY, USA.
| |
Collapse
|
3
|
Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 2013; 12:1069-78. [PMID: 23660515 PMCID: PMC4147963 DOI: 10.1016/j.arr.2013.04.003] [Citation(s) in RCA: 183] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2013] [Revised: 04/20/2013] [Accepted: 04/25/2013] [Indexed: 01/07/2023]
Abstract
Roles are emerging for natural killer (NK) cells beyond removing transformed cells. These include immune regulation and the elimination of senescent cells. Human ageing is associated with a decline in NK cell function. We propose some aspects of human ageing are due in part to reduced NK cell function. These include reduced vaccination efficacy and delayed resolution of inflammation.
Forming the first line of defence against virally infected and malignant cells, natural killer (NK) cells are critical effector cells of the innate immune system. With age, significant impairments have been reported in the two main mechanisms by which NK cells confer host protection: direct cytotoxicity and the secretion of immunoregulatory cytokines and chemokines. In elderly subjects, decreased NK cell activity has been shown to be associated with an increased incidence and severity of viral infection, highlighting the clinical implications that age-associated changes in NK cell biology have on the health of older adults. However, is an increased susceptibility to viral infection the only consequence of these age-related changes in NK cell function? Recently, evidence has emerged that has shown that in addition to eliminating transformed cells, NK cells are involved in many other biological processes such as immune regulation, anti-microbial immune responses and the recognition and elimination of senescent cells, novel functions that involve NK-mediated cytotoxicity and/or cytokine production. Thus, the decrease in NK cell function that accompanies physiological ageing is likely to have wider implications for the health of older adults than originally thought. Here, we give a detailed description of the changes in NK cell biology that accompany human ageing and propose that certain features of the ageing process such as: (i) the increased reactivation rates of latent Mycobacterium tuberculosis, (ii) the slower resolution of inflammatory responses and (iii) the increased incidence of bacterial and fungal infection are attributable in part to an age-associated decline in NK cell function.
Collapse
|